Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11157975 | 0.89 | MEN1 (0.62) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL2073208 | 0.89 | MAPT (0.65) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL4907597 | 0.89 | LMNA (0.67) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL6311629 | 0.89 | MAPT (0.66) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL2075250 | 0.88 | ALDH1A1 (0.72) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL7971165 | 0.88 | MEN1 (0.53) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL4906987 | 0.87 | SMN1; SMN2 (0.53) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL4905943 | 0.86 | POLB (0.62) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL31578670 | 0.84 | ALDH1A1 (0.60) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL25410911 | 0.82 | LMNA (0.73) | MEN1KMT2AMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8049013-B2 | 5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| EP-1537091-B1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100069352-A1 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| EP-1537091-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| US-6809110-B2 | NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID | HOFFMANN-LA ROCHE INC. | 2004-10-26 | — | — | US | disclosed |
| US-20040110807-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | MEN1 4859/4885KMT2A 3602/4885MAPT 1858/4885 |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | MEN1 4855/4885KMT2A 3530/4885MAPT 1786/4885 |
| US-20100069352-A1 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, HCRTR1 | MEN1 724/4885KMT2A 2524/4885MAPT 3293/4885 |
| US-20040110807-A1 | Thiazole derivatives | SLC5A1, GPR119, INSR | MEN1 623/4885KMT2A 4113/4885MAPT 4327/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | MEN1 4855/4885KMT2A 3530/4885MAPT 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.